The Role of Co-Morbidity in the Selection of Antidiabetic Pharmacotherapy in Type-2 Diabetes

Cardiovascular Diabetology - United Kingdom
doi 10.1186/1475-2840-12-62
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Role of Conventional Oral Antidiabetic Drugs in Management of Type 2 Diabetes Mellitus

International Journal of Research in Medical Sciences
2017English

Pdb94 - Initial Antidiabetic Pharmacotherapy Prescribed to Patients With Newly Diagnosed Type-2 Diabetes in a Commercial Health Plan in the United Stated

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Antidiabetic Drugs of Type 2 Diabetes and Obesity

2016English

Pharmacotherapy in Type 1 Diabetes

Canadian Journal of Diabetes
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2013English

The Potential Role of Sodium Glucose Co-Transporter 2 Inhibitors in the Early Treatment of Type 2 Diabetes Mellitus

International Journal of Clinical Practice
Medicine
2015English

The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes

Journal of Diabetes Research
EndocrinologyMetabolismDiabetes
2016English

Cardiovascular Safety of Non-Insulin Pharmacotherapy for Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2017English

Adherence to Oral Antidiabetic Medication in Type 2 Diabetes Mellitus Clients in the Volta Region of Ghana

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy